since most of the biological effects of glucocorticoids are attributed to their genomic actions on target genes in many types of cells [7] .
To investigate GRH receptor gene expression at mRNA levels, a highly-sensitive method is required, because GRH receptor mRNA content is very low even in the anterior pituitary [8] . Conventional Northern blot analysis of total RNA in the pituitary tissue of a single rat fails to detect this lowabundant mRNA. Polymerase chain reaction (PCR) is extremely sensitive and quantitative PCR is useful for examining the regulation of GRH receptor mRNA levels.
We previously established a competitive reverse transcription (RT)-PCR method [9, 10] . In the present study, we examined the The primary culture system of rat anterior pituitary cells was prepared as previously described [11] . The cells were treated with Dex 4 days after preparation and the dose-and time-dependent effects of Dex on GRH receptor mRNA levels were examined with total RNA extracted from the treated cells. In a separate series of experiments, a glucocorticoid receptor-specific antagonist, RU38486 (Roussel UCLAF, Paris, France), was added to the cells in the presence of Dex. For in vivo studies, male adult Wistar rats were used. Dex was administered to the rats by ip injection and they were killed by decapitation 24 h after the single injection.
Total RNA was extracted from rat anterior pituitary tissues to examine GRH receptor mRNA levels. In the next series of experiments, rats underwent adrenalectomy to remove endogenous glucocorticoids. Vehicle and Dex were administered to the glucocorticoid-deficient animals. Anterior pituitary tissues were obtained 3 days after surgery to examine GRH receptor mRNA levels. Statistical comparisons were made by one-way analysis of variance and Student's ttest, with P<0.05 being considered significant.
Results
Cultured rat anterior pituitary cells were treated with Dex at several concentrations for 24 h. GRH receptor mRNA levels were significantly increased by Dex at a concentration of 5 nM and the maximal effect was noted at 25 nM (Fig. 1) . Time-course effects of Dex were examined in the next series of experiments.
The concentration of Dex was adjusted to 5 nM in these experiments. GRH receptor mRNA levels were not altered by 2-h incubation with Dex, but the 6-h incubation significantly increased GRH receptor mRNA levels in the cultured rat anterior pituitary cells (Fig. 2) . This stimulatory effect of Dex persisted until at least 24 h after treatment. A glucocorticoid receptor specific antagonist, RU 38486, significantly inhibited Dex-induced increase in GRH receptor mRNA levels (Fig. 3) .
In the first series of in vivo studies, a single i.p injection of Dex had not significantly altered pituitary GRH receptor mRNA levels 24 h after the injection (Fig. 4) . Changes in GRH receptor mRNA levels were similar when much lower doses of Dex were used in the same protocol. Even longer exposure to a high dose (200 µg/rat) of Dex for up to 3 weeks did not significantly alter pituitary GRH receptor mRNA levels. Figure 5 shows the effects of adrenalectomy on pituitary GRH receptor mRNA levels in rats. GRH receptor mRNA levels were significantly decreased 3 days after adrenalectomy, [13, 14] . In the present study, stimulatory actions of Dex in GRH receptor mRNA levels were delayed, requiring more than 2 h at least. This also suggests that the Dex-induced increase in GRH receptor mRNA levels might be due to indirect effects on the stability of GRH receptor mRNA.
Administration of Dex to the rats did not cause a significant increase in GRH receptor mRNA levels. Although a high dose of Dex (200 ,ug/rat) was administered to the rats daily for a prolonged period (up to 3 weeks), pituitary GRH receptor mRNA levels were not significantly increased. These results indicate that pituitary GRH receptor mRNA levels are less affected by glucocorticoid excess in vivo. A considerable number of reports have previously shown that the effects of glucocorticoids on the CH-regulatory system appear to be different, sometimes even opposite, on comparison of in vitro and in vivo results [15] . Hypothalamic modification by GRH and somatostatin, and metabolic influence may modify glucocorticoid actions, and we do not preclude the possibility that the doses and ways of Dex administration might be responsible for the lack of its stimulatory effect on GRH receptor mRNA levels in vivo.
On the other hand, GRH receptor mRNA levels were significantly lowered in glucocorticoiddeficient rats after adrenalectomy.
Furthermore, replacement of Dex normalized the pituitary GRH Effects of dexamethasone (DEX) injection on pituitary GRH receptor mRNA levels in rats. DEX (40 or 200 pg/rat) was administered to male rats by ip injection for 3 days. Six animals were used in each group. 
